Breakthrough in FIP Treatment: Wedgewood Pharmacy Launches Game-Changing Molnupiravir for Cats!
Wedgewood Pharmacy Introduces Compounded Molnupiravir for Treating Feline Infectious Peritonitis (FIP)
Wedgewood Pharmacy has announced the addition of molnupiravir to its veterinary formulary, offering a new treatment option for Feline Infectious Peritonitis (FIP), a devastating viral disease that affects approximately 15,000 cats annually in the U.S. Molnupiravir, originally developed for human viral infections like COVID-19, has shown promise in studies as both a primary and rescue treatment for FIP, particularly in its various forms: Effusive, Non-effusive, Neurological, and Ocular.
As the first U.S. veterinary compounding pharmacy to offer molnupiravir in feline-friendly formulations, Wedgewood now provides veterinarians with multiple dosing options, including 50mg/ml and 100mg/ml flavored oral oil suspensions, and capsules in doses ranging from 25mg to 80mg. This variety of formulations allows for more targeted treatment of FIP, depending on the severity and type of infection.
The decision to introduce molnupiravir came after Wedgewood's product team consulted with FIP Global Cats and reviewed key research studies. In one study led by Dr. Okihiro Sase of the You-Me Animal Clinic in Japan, the majority of 18 cats treated with molnupiravir achieved remission with minimal side effects. Another study by researchers including Meagan Roy and Samantha J. M. Evans confirmed the drug's potential in treating FIP. However, Wedgewood emphasizes that its molnupiravir formulation is not identical to those used in the studies and makes no claims regarding its safety or efficacy.
Dr. Alejandro Bernal, CEO of Wedgewood Pharmacy, highlighted the importance of this new treatment: “Molnupiravir represents a significant step forward in the battle against FIP, providing veterinarians with innovative tools to improve the quality of life for their feline patients. By offering flavored formulations, we make it easier for pet owners to administer this treatment, giving cats a better chance at recovery."
Nicole Jacque, Co-Founder of FIP Global CATS, expressed her enthusiasm for the launch, noting that molnupiravir has already proven effective in countries where it is legally available. “This launch is a crucial advancement for FIP treatment in the U.S. It offers a new hope for cats that may have developed resistance to other antiviral treatments, bringing us closer to establishing safe, regulated FIP treatment as the standard of care worldwide.”
Wedgewood’s compounded molnupiravir is offered at dosages consistent with international veterinary research (10-20 mg/kg) and tailored to the specific needs of each cat. This personalized approach aims to improve recovery rates for cats affected by this often-fatal disease.
Veterinarians and cat owners can find more information and access educational resources about molnupiravir at Wedgewood.com/molnupiravir.
